Nasdaq
$0.9026▲ 0.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $70.2MShares out 77.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 2d agoAfter-hours26.10.23 05:308-KKey event#●●●
Cardiff Oncology, Inc.
Cardiff Oncology held a special meeting of stockholders on October 22, 2026, where shareholders approved an amendment to increase the authorized capital stock from 170 million to 320 million shares and common stock from 150 million to 300 million shares. This approval provides the company with the necessary authorization for potential future share issuances.…more
$0.9026+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14Pre-market26.09.14 22:288-KKey event
Cardiff Oncology, Inc.
Cardiff Oncology has reached a settlement to resolve litigation with Nerviano Medical Sciences regarding patent inventorship and their license agreement. The companies amended their 2017 license agreement to strengthen collaboration on the clinical development of onvansertib and granted Nerviano a board observer seat and a position on the Scientific Advisory Board.…more
$0.9026+0.03%vs prev closeView filingShare - 8.26After-hours26.08.27 05:05DEFA14AOther
Cardiff Oncology, Inc.
Cardiff Oncology will hold a special meeting of stockholders on October 22, 2026, to vote on increasing the authorized capital stock from 170 million to 320 million shares and the authorized common stock from 150 million to 300 million shares. This increase in authorized shares is a preparatory step for potential future capital raising, which implies a risk of dilution for existing shareholders.…more
$0.9026+0.03%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoRegular26.10.22 02:56#●●●#●●●
Cardiff Oncology Receives FDA Orphan Drug Designation for CMML Treatment…more
Cardiff Oncology's treatment for chronic myelomonocytic leukemia has been granted Orphan Drug Designation by the FDA. This status provides the company with potential tax incentives and expedited development pathways.…more
$0.9026+0.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.14Pre-market26.09.14 21:30
●●●●●●●● ●●●●● ●●●●●●
Cardiff Oncology has reached a settlement with Nerviano Medical Sciences to resolve all outstanding disputes regarding their 2017 license agreement. This agreement clears the path for the continued clinical development of their lead cancer drug candidate, onvansertib.…more
$0.9026+0.03%vs prev close - 9.2Pre-market26.09.02 20:00
●●●●●●●● ●●●●● ●●●●●●
Cardiff Oncology announced its participation in two upcoming investor conferences in September to discuss its cancer therapy development. As these events are for corporate outreach and information sharing, the impact on the stock price is expected to be neutral.…more
$0.9026+0.03%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report